Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1942 1
1943 1
1944 1
1945 2
1946 3
1947 4
1948 3
1949 2
1951 4
1952 2
1953 5
1954 5
1955 7
1956 1
1957 1
1958 2
1959 2
1960 1
1961 2
1962 1
1964 7
1965 5
1967 3
1968 2
1969 1
1970 1
1974 3
1976 5
1977 1
1978 2
1979 1
1980 4
1981 4
1982 3
1983 2
1984 1
1985 8
1986 8
1987 8
1988 7
1989 11
1990 7
1991 11
1992 8
1993 11
1994 6
1995 5
1996 8
1997 11
1998 6
1999 8
2000 3
2001 8
2002 7
2003 5
2004 7
2005 12
2006 10
2007 9
2008 5
2009 8
2010 12
2011 12
2012 14
2013 26
2014 14
2015 7
2016 6
2017 5
2018 5
2019 14
2020 11
2021 18
2022 14
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

442 results

Results by year

Filters applied: . Clear all
Page 1
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Tawbi HA, et al. N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970. N Engl J Med. 2022. PMID: 34986285 Free PMC article. Clinical Trial.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Bellmunt J, et al. N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17. N Engl J Med. 2017. PMID: 28212060 Free PMC article. Clinical Trial.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Powles T, et al. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. Lancet Oncol. 2020. PMID: 32971005 Clinical Trial.
Cauda equina syndrome.
Findlay G, Macfarlane R. Findlay G, et al. Among authors: macfarlane r. J Neurosurg Spine. 2009 Jul;11(1):90-1; author reply 91-2. doi: 10.3171/2009.2.SPINE08673L. J Neurosurg Spine. 2009. PMID: 19569949 No abstract available.
Determinants of Vestibular Schwannoma Growth.
Sethi M, Borsetto D, Bance M, Cho Y, Gair J, Gamazo N, Joannides A, Jefferies S, Mannion R, Macfarlane R, Donnelly N, Tysome JR, Axon P. Sethi M, et al. Among authors: macfarlane r. Otol Neurotol. 2021 Jun 1;42(5):746-754. doi: 10.1097/MAO.0000000000003043. Otol Neurotol. 2021. PMID: 33273313
The changing face of tumor phenotypes.
Macfarlane R, Sauter ER. Macfarlane R, et al. Biomark Med. 2012 Oct;6(5):563-6. doi: 10.2217/bmm.12.66. Biomark Med. 2012. PMID: 23075235 Free article. No abstract available.
442 results